200 related articles for article (PubMed ID: 20658130)
21. Attitudinal survey of voluntary reporting of adverse drug reactions.
Eland IA; Belton KJ; van Grootheest AC; Meiners AP; Rawlins MD; Stricker BH
Br J Clin Pharmacol; 1999 Oct; 48(4):623-7. PubMed ID: 10583035
[TBL] [Abstract][Full Text] [Related]
22. Healthcare personnel's experience of reporting adverse drug reactions in Baghdad city: cross-sectional study.
Hussain SA; Abbas AN; Habeeb SA; Abd-Ali AK; Abdulrahman ZS
Int J Clin Pharm; 2019 Oct; 41(5):1307-1313. PubMed ID: 31240554
[TBL] [Abstract][Full Text] [Related]
23. Public confidence in ADR identification and their views on ADRreporting: mixed methods study.
Jarernsiripornkul N; Patsuree A; Krska J
Eur J Clin Pharmacol; 2017 Feb; 73(2):223-231. PubMed ID: 27837337
[TBL] [Abstract][Full Text] [Related]
24. Knowledge, attitudes, and perceptions of pharmacists to adverse drug reaction reporting in Iran.
Vessal G; Mardani Z; Mollai M
Pharm World Sci; 2009 Apr; 31(2):183-7. PubMed ID: 19116770
[TBL] [Abstract][Full Text] [Related]
25. The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study.
Schutte T; van Eekeren R; Richir M; van Staveren J; van Puijenbroek E; Tichelaar J; van Agtmael M
Naunyn Schmiedebergs Arch Pharmacol; 2018 Jan; 391(1):17-26. PubMed ID: 29063137
[TBL] [Abstract][Full Text] [Related]
26. Spontaneous ADR reports as a trigger for pharmacogenetic research: a prospective observational study in the Netherlands.
van Puijenbroek E; Conemans J; van Grootheest K
Drug Saf; 2009; 32(3):255-64. PubMed ID: 19338383
[TBL] [Abstract][Full Text] [Related]
27. Feedback for patients reporting adverse drug reactions; satisfaction and expectations.
Rolfes L; van Hunsel F; van Grootheest K; van Puijenbroek E
Expert Opin Drug Saf; 2015 May; 14(5):625-32. PubMed ID: 25766456
[TBL] [Abstract][Full Text] [Related]
28. Reporting of adverse drug reactions by general practitioners: a questionnaire-based study in the Netherlands.
Passier A; ten Napel M; van Grootheest K; van Puijenbroek E
Drug Saf; 2009; 32(10):851-8. PubMed ID: 19722728
[TBL] [Abstract][Full Text] [Related]
29. Medical students as adverse drug event managers, learning about side effects while improving their reporting in clinical practice.
Reumerman M; Tichelaar J; Richir MC; van Agtmael MA
Naunyn Schmiedebergs Arch Pharmacol; 2021 Jul; 394(7):1467-1476. PubMed ID: 33666715
[TBL] [Abstract][Full Text] [Related]
30. Medication safety knowledge, attitudes and practices among community pharmacists in Lebanon.
Hajj A; Hallit S; Ramia E; Salameh P;
Curr Med Res Opin; 2018 Jan; 34(1):149-156. PubMed ID: 28758813
[TBL] [Abstract][Full Text] [Related]
31. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
[TBL] [Abstract][Full Text] [Related]
32. 'Have we missed reporting adverse drug reactions under Revised National TB Control Programme?' - A mixed method study in Bengaluru, India.
Krishnappa L; Gadicherla S; Chidambaram P; Anuradha HV; Somanna SN; Naik PR; Das A; Narasimhaiah S; Nagaraja SB
Indian J Tuberc; 2020 Jan; 67(1):20-28. PubMed ID: 32192612
[TBL] [Abstract][Full Text] [Related]
33. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
[TBL] [Abstract][Full Text] [Related]
34. Reporting, handling, and subjective importance of adverse drug reactions among general practitioners: an exploratory cross-sectional survey.
Gahr M; Connemann B; Zeiss R; Schönfeldt-Lecuona C; Dreyhaupt J; Lazik C
Expert Opin Drug Saf; 2021 Aug; 20(8):979-985. PubMed ID: 34014779
[No Abstract] [Full Text] [Related]
35. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
[TBL] [Abstract][Full Text] [Related]
36. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
Tandon VR; Mahajan V; Khajuria V; Gillani Z
Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
[TBL] [Abstract][Full Text] [Related]
37. Adverse drug reaction reporting among health care workers at Mulago National Referral and Teaching hospital in Uganda.
Katusiime B; Semakula D; Lubinga SJ
Afr Health Sci; 2015 Dec; 15(4):1308-17. PubMed ID: 26958036
[TBL] [Abstract][Full Text] [Related]
38. Knowledge, attitude and practice of General Practitioners towards adverse drug reaction reporting in South of Iran, Shiraz (Pharmacoepidemiology report).
Peymani P; Tabrizi R; Afifi S; Namazi S; Heydari ST; Shirazi MK; Nouraei H; Sadeghi E; Lankarani KB; Maharlouei N
Int J Risk Saf Med; 2016 Mar; 28(1):25-31. PubMed ID: 27176754
[TBL] [Abstract][Full Text] [Related]
39. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.
Sharma PK; Misra AK; Gupta A; Singh S; Dhamija P; Pareek P
Indian J Pharmacol; 2018; 50(5):273-278. PubMed ID: 30636831
[TBL] [Abstract][Full Text] [Related]
40. Patients' experiences on adverse drug reactions reporting: a qualitative study.
Al Dweik R; Yaya S; Stacey D; Kohen D
Eur J Clin Pharmacol; 2020 Dec; 76(12):1723-1730. PubMed ID: 32661571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
